The characterization and management of focal liver lesions is a commonly encountered problem in radiology. While the imaging findings will often be diagnostic, in equivocal cases the decision of how to proceed may be challenging. The primary modalities for liver lesion characterization are multiphase contrast-enhanced computed tomography and magnetic resonance imaging. Most lesions have typical imaging features, and when taken in conjunction with patient demographics and biochemistry the diagnosis can usually be made. Ancillary imaging modalities such as contrast-enhanced ultrasound and hepatobiliary specific contrast agents are also useful. Cirrhotic livers present a challenge due to the spectrum of benign, dysplastic, and malignant nodules that can occur. The report should include information necessary for accurate staging, and published standardized reporting guidelines should be taken into consideration. A decision to proceed to biopsy should be made only after multidisciplinary review of the case. If biopsy is required, fine needle aspiration is usually sufficient, though core needle biopsy may be required in certain circumstances.
(FNH) and adenomas are more common in younger to middle-aged patients, whereas hemangiomas are found in all ages. All 3 lesions also have a female predilection. Exogenous estrogen such as oral contraceptive use can accelerate the development of adenomas and FNH, with the former also increased in prevalence in those using anabolic steroids or in glycogen storage disease. Other information that may be helpful include travel history (parasitic or viral infections) or history of primary malignancy.
Hemangiomas and FNH tend to be incidental findings and asymptomatic, though large lesions may cause right upper quadrant pain from mass effect and capsular distension. Adenomas and hepatocellular carcinoma (HCC) may present with acute symptoms secondary to rupture and subsequent hemoperitoneum.
The list of risk factors for the development of chronic liver disease and HCC is extensive. The most common causes worldwide are viral hepatitis (hepatitis B and C) and alcohol. Other causes include autoimmune liver diseases (autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis), metabolic disorders (hemochromatosis, Wilson's disease, alpha-1 antitrypsin), and, increasingly, nonalcoholic steatohepatitis is seen as a cause that may progress to cirrhosis [1, 2] .
Alpha-fetoprotein can be used as a biomarker in both primary and secondary liver malignancies, and its clinical utility can range from screening of high-risk patients to monitoring of therapy response and recurrence [3] . Similarly, detection of colorectal liver metastases is aided by monitoring carcinoembryonic antigen levels [4] .
Choosing an Imaging Modality
In most cases, liver masses are initially detected on ultrasound or single-phase computed tomography (CT). Magnetic resonance imaging (MRI) is the best modality for characterizing liver masses, due to its improved sensitivity and temporal and contrast resolution. MRI is also preferred in cases when iodinated contrast is contraindicated due to allergy, or in young adults or pediatric patients. In cases of limited resource availability, however, multiphasic CT (arterial, portal venous, and delayed phases) can also adequately characterize liver masses. Often the decision of where to send a patient for imaging depends on local expertise and resources, as well as the likelihood of referral to a tertiary care centre for management.
In the case of MRI, either extracellular or hepatocytespecific contrast agents (eg, gadoxetic acid) can be used. The underlying mechanism of the latter agent involves uptake and retention of the agent by functioning hepatocytes, which peaks at 20 minutes, with excretion into the biliary system.
Benefits of hepatocyte-specific agents include functional assessment of liver and biliary excretion; improved sensitivity and accuracy for the detection of HCC and hypovascular metastases compared to CT and extracellular agents, respectively [5, 6] ; and ability to differentiate between lesions with hepatocytes that retain the agent (eg, FNH) from those that do not (ie, most adenomas) that have overlapping imaging features otherwise.
Hepatocyte-specific agents are not without its limitations. They are more expensive and require a longer imaging time. Arterial phase enhancement of lesions is less intense than with extracellular agents, and nonehepatocyte-containing lesions will become hypointense on equilibrium phase (3-5 minutes postinjection) resulting in a pseudowashout appearance, which limits the assessment of lesions such as hemangiomas. The utility of hepatocyte-specific agents in cirrhosis is controversial; as uptake of the agent is reduced as liver function is compromised, lesion conspicuity decreases. Well-differentiated hepatocellular carcinoma may retain contrast on hepatocyte phase imaging and overlap in appearance with high-grade dysplasia [6e8].
Positron emission tomography CT (PET-CT) has limited utility in the diagnosis of hepatic lesions, with its primary role to look for sites of extrahepatic disease. A negative PET scan does not exclude malignancy (in particular, HCC with reported sensitivities of only 60%) and a positive PET cannot differentiate among HCC, cholangiocarcinoma, or metastases [9] . In addition, heterogenous background liver activity makes detection of small lesions challenging [10] . Benign lesions such as FNH and hemangiomas tend to uptake fluorodeoxyglucose similarly to normal liver [11, 12] , thus increased uptake in a hepatic lesion in a patient with known primary malignancy and no clinical features of infection is suggestive of metastases.
Contrast-enhanced ultrasound (CEUS) is a wellestablished modality for the evaluation of focal liver lesions and is a useful adjunct or alternative to CT/MRI. It requires the injection of an intravascular microbubble agent as contrast, and has benefits including real-time observation of enhancement patterns, no ionizing radiation, safety in renal impairment, and is relatively easy to use. Sensitivity and specificity may be reduced in livers that are highly attenuating or coarsened, as well as in deeply located lesions (>8 cm from the skin surface). Contrast-enhancement patterns in arterial, portal venous, and late phases are similar to that on CT or MRI with some exceptions. Features such as early arterial enhancement and washout may be easier to appreciate on CEUS due to improved temporal resolution and the purely intravascular localization of the microbubbles [13, 14] .
Size Matters
Lesions larger than 1 cm can be characterized in most cases. Small hepatic lesions (<1 cm) are difficult to characterize and biopsy, but have a high probability of being benign (>80% even in patients with known malignancy) [15, 16] , thus close clinical follow-up and monitoring for progression may be the next most appropriate step. In most cases these lesions represent cysts, hemangiomas, or biliary hamartomas.
Lesions <0.5 cm in patients without risk factors (ie, no known malignancy, hepatic dysfunction, hepatic malignancy risk factors, or symptoms attributable to the liver) do not require follow-up [17] .
Radiologic Features of Hepatic Masses Without Underlying Liver Disease

Hemangioma
Hemangiomas are a benign mesenchymal tumour of endothelial cells, composed of multiple vascular channels, and are the most common benign liver tumour. On ultrasound (Figure 1 ), the typical appearance is a well-defined, echogenic, homogenous mass, which often shows faint posterior acoustic enhancement [18] . On contrast-enhanced CT ( Figure 2 ), they exhibit typical discontinuous peripheral nodular enhancement with centripetal fill-in of the lesion within 15 minutes. The lesion density should be equal to or hyperdense to the aorta on all phases, with contrast enhancement persisting on delayed imaging. On MRI (Figure 3 ), hemangiomas are T1 hypointense, intensely T2 bright, enhance in a similar fashion to CT postcontrast, and are hypointense on hepatocyte phase when using hepatobiliary agents [19] .
Atypical appearances include giant and flash-filling hemangiomas, which may show central heterogeneity and rapid arterial filling, respectively. Both will still show the characteristic marked T2 hyperintensity [20] .
Focal Nodular Hyperplasia
FNHs are the second most common benign liver tumour, characterized by a focal hyperproliferation of hepatocytes. A helpful distinguishing feature is a central scar (which is actually composed of blood vessels and bile ducts) though this is not seen in all FNHs [21] and scars may be seen in other lesions both benign and malignant. FNHs are of similar echotexture to normal liver parenchyma on ultrasound, hence the classic description of a stealth lesion that may only be detected by observing mass effect on surrounding structures and a hypervascular spoke-wheelelike appearance of the central scar on colour Doppler (Figure 4 ). On both contrastenhanced CT and MRI, FNHs are demonstrate homogenous hypervascularity on arterial phase, isointensity on portal venous phase and delayed enhancement of the central scar ( Figures 5-6 ). Additional MRI features include T2 hyperintensity of the scar with contrast retention in the lesion due to lack of normal biliary drainage and hypointensity of the scar on hepatocyte phase [22] . Increase in size is uncommon but may be seen in up to 17% of lesions [23] .
Hepatic Adenoma
Almost exclusively seen in young females in estrogenic environments, young males on anabolic steroids or in glycogen storage disease, hepatic adenomas may contain fat, hemorrhage, necrosis, or calcification and thus are quite variable in their imaging appearances. Adenomas should be more closely monitored as they are at risk for hemorrhage or malignant transformation and may require surgical resection.
On ultrasound they are generally well defined, echogenic or heterogenous, hypervascular with colour Doppler, and encapsulated ( Figure 7A ). Lipid and hemorrhage may be seen on noncontrast CT as hypo-and hyperdense foci respectively. On MRI, the lesions are heterogenous on T1and T2-weighted imaging. The presence of macroscopic or microscopic lipid may be better appreciated with fat saturation or in-and-out of phase imaging respectively. ). Adenomas will usually not retain hepatocyte-specific contrast on delayed phase imaging, and may show a nonenhancing central scar that helps distinguish it from FNH. Adenomas can be difficult to differentiate from HCC as both are hypervascular, may wash out, and are hypointense on hepatobiliary phase imaging. However, the demographics are different and adenomas will not show invasive features [24, 25] .
Current pathologic classification of hepatic adenomas divides them into subtypes, some of which have been shown to have differentiating features on MRI. These include inflammatory adenomas that tend to have a T2 hyperintense rim (atoll sign) and may retain contrast on hepatobiliary phase imaging (mimicking an FNH), HNF-1aemutated adenomas that are more likely to contain significant intralesional lipid and b-catenin-mutated lesions, which have less specific imaging features but carry a higher risk of malignant transformation [25e27].
Metastases
Hepatic metastases have variable appearances depending on the tissue of origin and histologic grade. On ultrasound, most metastases are hypoechoic and some may be seen as bullseye or target lesions in which an iso-or hyperechoic mass is surrounded by a hypoechoic halo ( Figure 10 ). This appearance is most common with aggressive primaries such as lung, breast, and colon carcinomas [28] .
Hypervascular metastases ( Figure 11 ) including neuroendocrine, thyroid, melanoma, and renal cell primaries may be hyperechoic on ultrasound and hyperdense on CT in the arterial phase. Hypovascular metastases from epithelial tumours such as colon, lung, breast, and gastric carcinomas, are hypoechoic on ultrasound, and on contrast-enhanced CT are hypodense centrally, often with continuous and irregular peripheral rim enhancement [29] . Nonenhancing cystic liver metastases can be seen with mucinous primaries such as ovarian or colon carcinoma.
On MRI, metastases are usually hypointense on T1 and hyperintense on T2, with enhancement patterns which parallel those seen on CT. Diffusion weighted imaging is very useful for detection with reported sensitivities and specificities of 88%-91% [30] . Hepatobiliary contrast agents are sensitive for lesion detection, as metastases are conspicuously hypointense on hepatocyte phase imaging ( Figure 12 ) [31] .
Cholangiocarcinoma
Arising from intra-or extrahepatic bile duct epithelium, cholangiocarcinomas also have a wide spectrum of appearances. They can be classified anatomically (intrahepatic, extrahepatic, or perihilar/Klatskin [32] or morphologically (mass forming, periductal infiltrating, and intraductal). Common associated findings on any modality include capsular retraction and dilated intra and/or extrahepatic bile ducts (Figures 13-15 ).
On ultrasound, a definitive mass is usually not seen or is ill defined, with the only indirect evidence being biliary duct dilation. On CT, cholangiocarcinomas may be peripherally enhancing on arterial phase with progressive patchy enhancement centrally, and on delayed phase enhancement will persist. Portal vein invasion and enlarged periportal nodes may also be seen.
On MRI, cholangiocarcinomas are T2 hyperintense with central hypointensity from fibrosis, T1 iso-or hypointense, and arterially hypovascular also with delayed persistent enhancement. Magnetic resonance cholangiopancreatography may reveal the site of obstruction and the extent of biliary tree involvement [32e34].
Radiologic Findings of Hepatic Masses in the Setting of Underlying Liver Disease
Nodules in chronic liver disease/cirrhosis arise as a result of chronic parenchymal insults, and range from benign regenerative nodules (RN) to premalignant dysplastic nodules (DN) to malignant hepatocellular carcinoma. Evaluation of these lesions may be challenging due to the background parenchymal heterogeneity and fatty infiltration, often multifocal involvement and variable appearances.
Regenerative Nodules
RNs are well circumscribed, focal proliferations of normal functioning hepatocytes. They are usually small (<2 cm) and occult on ultrasound and CT, though occasionally hyperdense to normal liver on noncontrast CT due to iron deposition. Postcontrast they may be isodense to slightly hypoattenuating on portal venous phase. On MRI, RNs are low signal intensity on T2 (again due to iron content), variable on T1, may display signal loss on outof-phase gradient recalled echo sequences, and on postcontrast imaging will be isointense or slightly hypointense to liver parenchyma. Hepatocyte phase will show retention of contrast ( Figure 16) [35e38].
Dysplastic Nodules
DNs pathologically show abnormal hepatocyte growth but lack definite histopathologic findings of malignancy. Depending on the degree of dysplasia, they may be classified as low or high grade. Similar to RNs, the majority of DNs are not apparent on ultrasound. On contrast-enhanced CT, DNs are usually not hypervascular but infrequently may show early arterial enhancement according to the degree of hepatic arterial neovascularization, which tends to correlate with the severity of dysplasia ( Figure 17 ).
MRI findings are variable, though on T1-weighted imaging, DN are usually iso-to hyperintense, and may show T2 hypointensity (lower grade lesions) or slightly higher T2 signal in higher grade nodules ( Figure 18 ). Similar to CT, following gadolinium, most DNs are hypovascular. However, where arterial enhancement is seen, concern should be raised for higher grade dysplasia though generally there is no portal venous washout. High-grade dysplastic nodules may appear hypointense on hepatocyte phase imaging with hepatocellular agents, a feature concerning for higher risk for malignant 
Hepatocellular Carcinoma
HCC shows a range of pathology from well-differentiated lesions (which may be difficult to differentiate from highgrade dysplastic nodules) to poorly differentiated malignancy. Lesions may contain fat, hemorrhage, or necrosisdfeatures that are reflected in its variable appearances on all imaging modalities. The sonographic appearance may be hypo-or hyperechoic (due to fat content), and a capsule may be seen. Small lesions are indistinguishable from regenerative and dysplastic nodules on ultrasound, particularly when small (<2 cm).
On CT, HCC is usually hypodense on unenhanced CT, heterogenously hypervascular on arterial phase, iso-to hypodense (early washout) on portal venous phase, and hypodense (washout) to liver parenchyma on delayed phases ( Figure 19 ). The presence of washout distinguishes HCC from regenerative nodules and arterioportal shunts. On contrast enhanced ultrasound, the enhancement pattern mimics that of CT ( Figure 20) .
On MRI, HCC has variable signal intensity on T1weighted images, and on T2 is usually mildly increased although well-differentiated lesions may be iso-or hypointense to liver. Larger tumours tend to have more heterogenous signal intensity on all sequences due to the presence of hemorrhage, fat, or necrosis. Fat may be identified by signal loss on out-of-phase (microscopic) or fat-saturated sequences (macroscopic) ( Figure 21) .
Hemorrhage tends to appear as T1 hyperintensity and T2 hypointensity with the reverse pattern seen with necrosis. Although most HCCs will enhance avidly on arterial phase with delayed phase washout, 10%-20% of lesions may be hypovascular (seen in both well and poorly differentiated HCC) ( Figure 22 ) [42, 43] .
Other findings in HCC may include diffusion restriction, a T1 and T2 hypointense tumour capsule (typically in large lesions, seen in 60%-82%), and vascular invasion of the portal or hepatic veins with enhancing tumour thrombus. Other common patterns include a nodule within a nodule appearance of a focus of T2 increased signal intensity (HCC) arising from a hypointense dysplastic nodule, satellite nodules ( Figure 23 ), and mosaic pattern characterized by confluent small nodules separated by fibrous septa and areas of necrosis. HCC is typically hypointense to liver parenchyma on 20-minute delayed images using hepatocellular agents, though 5%-12% of HCC (generally well differentiated) can be iso-or hyperintense [35, 36, 38, 44] . Imaging findings of focal liver lesions with and without association with chronic liver disease are summarized in Table 1 .
Reporting Considerations/Guidelines
What to Include in the Report
For any focal liver lesion, the report should include the size, margins, hepatic segment where it is located, enhancement and signal characteristics, solitary versus multiple lesions, the presence of any background liver disease (hepatomegaly, nodular contour, heterogenous parenchyma, fatty infiltration) or stigmata of portal hypertension, and interval change from any previous imaging (Table 2) .
For lesions suspected to be malignant, the report should be tailored to emphasize specific terminology and help guide management. For example, a number of staging systems exist for HCC, with the commonly used TNM Classification [45, 46] and Barcelona (BCLC) [47] systems variably incorporating lesion size, multiplicity, presence of vascular invasion (specifically a major portal or hepatic vein branch), direct extension into adjacent organs, regional node involvement, and presence of distant metastases. For surgical or interventional radiology planning, emphasis should also be placed on the lesion location and proximity to as well as integrity of major vascular and biliary structures.
The latest published guidelines (2011) from the American Association for the Study of Liver Diseases uses the BCLC system, and state that lesions larger than 1 cm that have typical arterial hyperenhancement and venous or delayed washout on multiphasic contrast-enhanced CT or MRI are diagnostic of HCC. If these characteristics are not met on a single modality, the alternate modality should be performed. If neither modality is diagnostic then biopsy should be considered. Most lesions <1 cm detected on surveillance ultrasound are more likely to be cirrhotic nodules rather than HCC, however should be followed at 3-month intervals. Any new nodules measuring more than 1 cm or that enlarge should be further investigated with contrast-enhanced crosssectional imaging [48, 49] .
RECIST
The Response Evaluation Criteria in Solid Tumors (RECIST) is a set of published rules for defining change in tumour burden. Last updated as version 1.1 in October 2008, the guidelines include the selection of target lesions, how to make reproducible measurements using the longest in-plane diameter, an explanation of how to measure over serial studies, and specific definitions of tumour response, stability, and progression [50] . RECIST is applicable to liver lesions, and is particularly useful to objectively evaluate tumour burden in patients undergoing multiple imaging studies for surveillance or assessing response to systemic treatment. RECIST is not without its limitations, however, including that of measurement variability and lack of volumetric assessment, and it does not take into account changes in tumour viability/metabolic activity depicted by changes in lesion enhancement [51] . For HCC, this has been further addressed by the modified RECIST criteria (mRECIST) developed by the American Association for the Study of Liver Diseases, which takes into consideration enhancement characteristics [52] . 
LI-RADS
The Liver Imaging Reporting and Data System (LI-RADS) was developed by panels of experts and is endorsed by the American College of Radiology to provide a framework to standardize CT and MR reporting of suspected HCC in high-risk patients. Lesions are scored on a scale from 1-5 as probability of malignancy increases. Imaging features taken into consideration when assigning a LI-RADS score include mass-like appearance, size, arterial phase enhancement, the presence of washout and/or a capsule, and threshold growth.
Additional modifiers include the presence of venous invasion and any previous locoregional treatment [53] .
In suspected HCC, when imaging findings are not definitive, the LI-RADS system helps to standardize interpretation and communicate the radiologist's degree of certainty to other clinicians in a consistent manner. LI-RADS also proposes management suggestions based on score [54] . For example, LI-RADS 3 lesions could potentially be followed up with repeat imaging, whereas LI-RADS 4 lesions may require biopsy and LI-RADS 5 lesions should be treated without biopsy. 
Decision to Biopsy
There is no single algorithm for deciding when and if to biopsy a focal liver lesion, as each patient should be evaluated by a multidisciplinary team and on a case-by-case basis. In the vast majority of cases, the combination of imaging, clinical, and biochemical evidence is diagnostic, with accuracies reported up to 98.2% [55, 56] and consequently biopsy is rendered unnecessary.
When the imaging is equivocal or atypical, the decision to biopsy should be carefully considered, based on potential complications. Percutaneous liver biopsy carries risks, including major hemorrhage (0.12%-1.6%) [57, 58] , especially with hemangiomas, adenomas, or hypervascular malignancy; tumour seeding (0.76%-1.6%) [59, 60] ; pain and discomfort; peritonitis; and lung or bowel injury [61] . The risks of the procedure need to be carefully weighed against the benefits of knowing the pathology.
When presented with an indeterminate lesion, several issues should be considered. The first is the degree of pretest probability. Patient age, gender, risk factors, history of malignancy, clinical presentation, previous imaging, and laboratory findings may sway a management decision towards surveillance, further imaging or biopsy for tissue diagnosis.
The second is whether knowledge of a specific diagnosis would alter management. A biopsy may be required if the result will determine either conservative, medical, minimally invasive, or surgical management; curative versus palliative treatment, or the need for neoadjuvant therapy. With the advent of personalized medicine, an emerging indication for focal liver lesion biopsy is biobanking disease tissue for genetic/molecular analysis, which may be for research purposes and/or development of tailored therapy. The third is whether the lesion is visible, safe, and accessible for image guided biopsy. Lesions that are too small or too deep may be technically challenging for US-or CT-guided biopsy. Absolute contraindications to percutaneous biopsy include uncorrectable coagulopathy, biliary obstruction, and existing infection. Relative contraindications include ascites, morbid obesity, hypervascular lesions, and amyloidosis [57] .
Periprocedural Planning
If a decision is made to proceed with image-guided percutaneous biopsy after a thorough discussion of the patient's case, several preparatory steps should be followed before the procedure.
The relevant history should be reviewed, including past medical conditions (including coagulopathy, history of viral hepatitis, or HIV), medications, allergies, and previous procedures. Written informed consent should be obtained from the patient (or designate), and there should be education regarding the procedure itself, risks, benefits, and alternatives. Recent bloodwork, including a complete blood count, and coagulation profile (international normalized ratio and prothrombin time) is obtained. At our institution, the recommended thresholds for performing biopsy are platelets >50 Â 10 9 /L, international normalized ratio 1.5, and prothrombin time 50 seconds.
Guidelines for stopping anticoagulant medications will vary depending on the institution and the patient-specific risk of stopping the medication. In general however, warfarin should be discontinued at least 5 days prior to the procedure, antiplatelets several days prior depending on the agent, and heparin (and related medications) 12-24 hours prior [57] .
The appropriate imaging modality should be selected, with ultrasound usually preferred (or CEUS if available) due to ability to follow the needle in real time. In select cases CT may be considered when ultrasound is not feasible such as when the lesion is not visible sonographically or the location is challenging. A trajectory should be selected that avoids bowel and lung, and traverses normal liver before entering the lesion to tamponade any potential bleeding. A subcostal approach is preferred, however, an intercostal approach may be unavoidable if the lesion is high in the liver. Care should be taken to avoid puncturing lung or injuring an intercostal artery and ensure the patient is able to follow breathing instructions. 
Percutaneous Biopsy Procedure
There are 2 primary methods for percutaneous imageguided biopsy: fine needle aspiration biopsy (FNAB) or core biopsy (CNB). Alternative biopsy methods not discussed here include transvenous and surgical/laparoscopic biopsy. For percutaneous biopsy, local anesthetic (1%-2% lidocaine, 10-20 mL) infiltration of the skin, subcutaneous tissues, and liver capsule is usually sufficient for pain control. However in some cases, conscious sedation may be necessary.
The diagnostic accuracy of FNAB is high (93.4%-98%) as are the sensitivity (76.5%-96.9%) and specificity (100%) [62e66], and this is the initial method of choice in most cases. A study by França et al. [67] showed that FNAB and CNB had a similar diagnostic accuracy. FNAB is performed at our centre with 2-4 passes with a 22-gauge spinal needle. FNAB is preferred in deeply seated lesions, patients with increased bleeding risk, sites adjacent to a dilated bile duct, major vessels or bowel, and small lesions [66] .
The diagnostic yield of FNAB will depend greatly on the cytopathology expertise at the institution and it is advantageous to have cytopathologist on site at the time of biopsy as this allows for rapid assessment of adequacy as well as sample quality feedback, and provides a provisional diagnosis. FNA is often sufficient to diagnose metastatic adenocarcinoma, though with other lesions, it will depend on the institutional cytopathology expertise and may have an increased risk of undersampling and providing little tissue architectural information. Specimens can be used to prepare direct smears and/or collected in an appropriate fixative [68e70].
Core biopsies are more commonly utilised in the diagnosis of diffuse liver disease. In the case of the focal lesion, CNB provides more tissue but due to the larger calibre needle, the bleeding risk is increased. Core biopsy can be performed with an 18-or 19-gauge needle, with technique options including using a coaxial outer sheath and gelfoam tract embolization (the latter in cases of increased bleeding risk). The specimen should be examined for adequacy, with a 1.5 cm total length usually sufficient to minimize sampling error [71] . Specimens should be collected in a 10% buffered formalin solution. CNB should be considered when FNA is non-diagnostic, when a larger amount of material is required for immunohistochemical staining or genetic analysis, and in some specific cases when the clinical question requires discrimination between well-differentiated HCC versus reactive hepatocellular nodules, or distinction of HCC from cholangiocarcinoma and metastases [66] . If uncertainty remains as to the type of biopsy required, consultation with pathology colleagues may be of benefit.
Postbiopsy, the patient should be observed for at least 2 hours, and for the first hour the patient should be on bed rest with vitals recorded every 15 minutes.
Example Cases
Case 1
A 76-year-old female with a remote history of a left popliteal leiomyosarcoma years ago represented a year later with a solitary bone metastasis in the proximal left tibia. A plan for curative above knee amputation was initiated, however on a staging chest/abdominal/pelvic CT a solitary liver lesion was found that was not present 2 years previously.
A dedicated multiphasic liver CT was subsequently performed ( Figure 24) , showing the lesion to have indeterminate characteristics, with arterial phase peripheral enhancement and apparent filling in, raising the possibility of a hemangioma. However the appearance on ultrasound performed a week later was not consistent with a hemangioma. Given the history of malignancy, and because the presence of distant metastases would preclude curative surgery, an FNA was performed of the liver lesion. Pathology showed the lesion to be a sarcoma metastasis. Based on this result, the planned surgery was cancelled and the patient was treated with local radiotherapy to the knee for pain management.
Case 2
A 61-year-old male with a history of Hepatitis C presented with an indeterminate liver lesion detected on CT. MRI was performed (Figure 25) , with the lesion showing T2 heterogenous hyperintensity, T1 hypointensity with hyperintense foci suggestive of hemorrhage, and some peripheral nodular arterial enhancement with some central but incomplete fill-in. Hemangioma was suggested as a possibility, however the atypical features prompted a recommendation for short-term follow-up MRI. Repeat MRI was performed in 6 months, which showed the lesion had significantly increased in size, with an enhancement pattern that remained indeterminate. Because of the rapid growth, risk factors, and indeterminate features on imaging, the lesion was biopsied and was shown to be a high-grade angiosarcoma, unfortunately a poor prognostic lesion.
Conclusion
Most solitary liver lesions can be accurately characterized with cross-sectional imaging, and the need for biopsy has decreased. The exact imaging work-up may vary, and depends on local expertise and resources. Biopsy may still be necessary in problematic cases or in unresectable lesions where management may be altered depending on the pathology result. The decision about whether (and how) to perform the biopsy requires careful consideration on a caseby-case basis and in a multidisciplinary management setting.
